Overview

Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Pevonedistat